4 Biotech Stocks That Could Break Through the Market

Four TSX biotech stocks could deliver outsized gains in 2023, as they are poised to break through the market soon.

| More on:
Workers use a microscope to do medical research in a modern laboratory.

Source: Getty Images

Most biotech stocks have low visibility with investors because the risks are pretty high. Nonetheless, the TSX has several names worth watching in 2023. Bausch Health (TSX:BHC) has appreciated substantially from year-end 2022, and three more could break through the market soon.

You can consider taking positions in BELLUS Health (TSX:BLU), Fennec Pharmaceuticals (TSX:FRX), or Knight Therapeutics (TSX:GUD) while the stock prices are low.

Strong upward momentum

Despite poor market conditions and a challenging macro environment, Bausch Health continues to display strong momentum. At $12.46 per share, the trailing one-year price return is -59.11%. However, the biotech stock beat the market year to date at +46.59% versus +6.17%.

The $4.51 billion specialty pharmaceutical company is a spin-off of Bausch & Lomb’s eyecare business. Bausch Health also incorporates various businesses focused on gastroenterology, neurology, dermatology, and international pharmaceuticals.

Management believes its leading durable brands and core business segments are growth drivers that will help advance global health.

Game changer

BELLUS Health is advancing a potential solution for refractory chronic cough called Camlipixant, or BLU-5937. This lead product candidate could be the game-changer for this $1.3 billion drug development company. The healthcare stock trades at $10.39 (-6.23% year to date) but could soar through the roof once BLU-5937 obtains approval for commercialization.

According to management, BELLUS has initiated the CALM Phase 3 clinical program for refractory chronic cough. Two trials (CALM-1 and CALM-2) to evaluate the efficacy, safety, and tolerability of Camlipixant are running concurrently. The development program is critical as the future of treating cough rests with the company.

Important breakthrough

Fennec Pharmaceuticals focuses on children with cancer and experiencing hearing loss due to the effect of chemotherapy. The $326.42 million commercial-stage specialty pharmaceutical company develops PEDMARK, which is devoted to fighting ototoxicity in pediatric cancer patients who receive cisplatin-based chemotherapy.

The sodium thiosulfate injection is the first and only Food and Drug Administration (FDA)-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumours. On January 31, 2023, the U.S. FDA granted Orphan Drug Exclusivity to PEDMARK.

Rosty Raykov, Fennec’s chief executive officer, said the approval represents an important breakthrough treatment option for the pediatric cancer community.” The stock is down 5.04% year to date ($12.43 per share), although the one-year price return is 73.85%.

Unique platform

Knight Therapeutics focuses on acquiring or in-licensing innovative pharmaceutical products for the home country and Latin America. Moreover, it acquires mature or “under-promoted” products from Big Pharma and licenses late-stage products.

The $583.46 million multinational specialty pharmaceutical company operates in Pan America, a unique platform with high-growth markets. Knight is involved in therapeutic areas such as oncology, hematology, infectious diseases, and other specialties.

Exelon, its top prescription product, is for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer’s and Parkinson’s disease. If you invest today, the share price is $5.12 (-1.16% year to date).

High risk. Tremendous reward

The profitability of biopharmaceutical companies depends mainly on the successful results of clinical trials and the proven effectiveness or safety of their lead drug candidates. From an investment perspective, the risks are high, but the potential rewards could be tremendous.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Investing

stock analysis
Dividend Stocks

Buy These TSX Dividend Shares Next Week

Are you looking for dividend stocks to add to your portfolio? Buy these picks next week!

Read more »

Shopping and e-commerce
Tech Stocks

1 Tech Stock You’ll Be Glad You Bought When the Bull Market Starts

Historically, tech stocks have done well during bull markets. Here’s one you’ll be happy you bought before the next bull…

Read more »

edit Safety First illustration
Dividend Stocks

3 of the Safest Dividend Stocks in Canada

These three dividend stocks are all high-quality companies with defensive operations, making them some of the safest investments in Canada.

Read more »

data analyze research
Bank Stocks

Better Buy: Royal Bank Stock or Bank of Nova Scotia?

Bank stocks appear cheap after the latest plunge. Is Royal Bank or Bank of Nova Scotia a buy today?

Read more »

A person builds a rock tower on a beach.
Dividend Stocks

3 Stocks to Anchor Your Portfolio in a Rocky Market

Three stocks are solid anchors in any portfolio today for their outperformance in a weak market and defiance of the…

Read more »

Metals and Mining Stocks

Better Metals Buy: Gold Stocks vs. Lithium Stocks

Gold is the evergreen choice as a hedge against inflation and weak markets. In contrast, battery metals may offer unique…

Read more »

Man making notes on graphs and charts
Bank Stocks

TD Bank Stock: A TSX Top Pick Amid U.S. Banking Rout?

TD Bank (TSX:TD) stock could prove a worthy bet for brave investors who aren't fearful over the recent wave of…

Read more »

edit Sale sign, value, discount
Tech Stocks

2 Cheap Tech Stocks to Buy Right Now

Many tech stocks offer exceptional returns compared to other stock sectors when the market is bullish. You can add to…

Read more »